SORBITOL-MANNITOL IN PLASTIC CONTAINER
Clinical safety rating
safeOther diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.
Sorbitol and mannitol are osmotic diuretics. They increase osmotic pressure in the glomerular filtrate, reducing water reabsorption and promoting diuresis. Mannitol also decreases intracranial and intraocular pressure by creating an osmotic gradient that draws water from tissues into the vasculature.
| Metabolism | Sorbitol is metabolized in the liver to fructose via sorbitol dehydrogenase; mannitol is minimally metabolized and is excreted unchanged by the kidneys. |
| Excretion | Renal: >95% as unchanged sorbitol and mannitol; negligible biliary/fecal elimination. |
| Half-life | Sorbitol: approximately 0.5-1 hour; mannitol: approximately 0.5-1.5 hours. In anuria, mannitol half-life may extend to 36 hours. |
| Protein binding | Negligible (<1%), no specific binding proteins. |
| Volume of Distribution | Sorbitol: ~0.3 L/kg; mannitol: ~0.2-0.3 L/kg; distributes primarily into extracellular fluid. |
| Bioavailability | Oral: 10-30% (sorbitol) due to incomplete absorption; mannitol oral absorption ~10-20%. IV: 100%. |
| Onset of Action | Oral: 30-60 minutes for cathartic effect; IV: minutes for osmotic diuresis. |
| Duration of Action | Oral: 1-2 hours for cathartic effect; IV: 1-3 hours for diuretic effect, depending on renal function. |
| Molecular Weight | 182.17 |
Intravenous infusion of 50 mL of a 25% sorbitol-25% mannitol solution administered over 10–20 minutes; may repeat once after 6–8 hours if needed.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in anuria or severe renal impairment (eGFR < 30 mL/min/1.73 m²). For eGFR 30–59 mL/min/1.73 m², extend dosing interval to every 12–24 hours and monitor serum osmolarity. No adjustment for eGFR ≥ 60. |
| Liver impairment | No dose adjustment required for Child-Pugh Class A or B. For Class C, use with caution and monitor for encephalopathy; consider reducing dose by 50%. |
| Pediatric use | Children: 2 mL/kg of 25% sorbitol-mannitol solution intravenously over 20–30 minutes; may repeat once after 8 hours. Maximum dose not to exceed 50 mL total. |
| Geriatric use | Initiate at lower end of dosing range (25–50 mL) due to increased risk of renal impairment and electrolyte disturbances. Monitor renal function and fluid status closely. |
| 1st trimester | Use only if clearly needed; no well-controlled studies in pregnant women. Animal studies suggest minimal risk. |
| 2nd trimester | Considered low risk; may cause fluid/electrolyte imbalance with prolonged use. |
| 3rd trimester | Avoid high doses near term due to possible fetal diuresis and electrolyte disturbances. |
Clinical note
Other diuretics may have additive effects Can cause fluid and electrolyte imbalances and pulmonary congestion.
| FDA category | Animal |
| Placental transfer | Crosses placenta; fetal serum levels approximate maternal levels after IV administration. |
| Breastfeeding | Sorbitol and mannitol are poorly absorbed orally; maternal IV administration may result in low levels in milk. Use with caution due to potential osmotic diarrhea in infant. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No teratogenic effects reported; insufficient data to assess risk in first trimester. Osmotic diuretics cross placenta; may cause electrolyte imbalance in fetus. Avoid in third trimester due to risk of fetal dehydration and electrolyte disturbances. |
| Fetal Monitoring | Monitor maternal serum electrolytes, osmolality, and urine output. Fetal assessment: amniotic fluid volume (risk of polyhydramnios with prolonged use) and fetal heart rate. |
| Fertility Effects | No known effects on fertility. |
■ FDA Black Box Warning
WARNING: Sorbitol-mannitol solution may cause severe electrolyte disturbances, including hyponatremia and hyperkalemia. Monitor serum electrolytes, renal function, and fluid balance closely. Use with caution in patients with renal impairment or congestive heart failure. Rapid administration can cause volume overload and pulmonary edema.
| Common Effects | edema |
| Serious Effects |
AnuriaSevere pulmonary congestionPulmonary edemaHypersensitivity to any component
| Precautions | Monitor for electrolyte imbalances, fluid overload, and renal function. Use cautiously in patients with cardiac disease, renal impairment, or pulmonary congestion. Avoid extravasation due to risk of tissue necrosis. Contraindicated in anuria or severe renal disease. |
| Food/Dietary | Avoid high-sodium foods during treatment; patients on a sodium-restricted diet should be monitored. No specific food interactions otherwise. |
| Clinical Pearls | Induces osmotic diuresis; monitor serum sodium and osmolality closely to avoid hypernatremia. Use with caution in renal impairment; may cause volume overload. Not for systemic absorption in routine bowel preparation. |
| Patient Advice | This solution may cause loose stools or diarrhea; stay hydrated unless restricted. · Inform your doctor if you have kidney disease, heart failure, or are on a low-sodium diet. · Do not mix with other medications; may be given as an enema or oral solution only as directed. |
Loading safety data…